493280.KQ IMBiologics
- Market cap
- KRW 194B
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 493280.KQ undervalued?
Graham numberThe Graham number of IMBiologics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IMBiologics fundamental analysis
No fundamental analysis for IMBiologics yet.
IMBiologics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IMBiologics
IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechan…
Full company profileFinancial statements of IMBiologics are not available yet.
IMBiologics dividends
IMBiologics has not paid dividends in the last 1 fiscal years.
Who owns IMBiologics
- Insiders 24.13%
- Institutions 27.99%
- Public & others 47.87%
- Shares outstanding 14.8M
IMBiologics company profile
- Company name
- IMBiologics
- Ticker
- 493280.KQ
- ISIN
- KR7493280002
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Gwanggyo Central Biz Tower, Suwon-si, South Korea, 16229
- Phone
- 82 31-8067-8172
- Website
- imbiologics.com
About IMBiologics
IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody-drug conjugate that targets HLA-G, a tumor-specific antigen; IMB-402, a concept anticancer vaccine bispecific antibody that utilizes the ePENDY (IgM-Agonist) modality to activate cancer cell-specific T cells. IMBiologics Corp. was founded in 2020 and is based in Suwon-si, South Korea.
IMBiologics management
6- Mr. Gyongsik Ha Ph.D.Founder, President, CEO & Chairman of the Board
- Mr. Wanjun KimChief of Management Support, CFO & Director · born 1976
- Mr. Insoo Jung Ph.D.COO, CBO & Head of Business Operation
- Ms. Chungmin Lee Ph.D.CTO, Head of R&D Center and Director · born 1979
- Ms. Chihye Park Ph.D.Chief Development Officer & Director · born 1973
- Ms. Jiyeon Hong Ph.D.Head of Business Development · born 1978